Pharmacodynamics of fluoroquinolones in experimental models of endocarditis

被引:38
作者
Andes, DR
Craig, WA
机构
[1] Univ Wisconsin, Dept Med, Madison, WI 53792 USA
[2] William S Middleton Mem Vet Adm Hosp, Madison, WI USA
关键词
D O I
10.1086/514624
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We calculated the magnitude of various serum pharmacodynamic parameters for fluoroquinolones in models of experimental endocarditis (EE) described in the literature, Nineteen publications contained data that allowed calculation of these parameters. Data were available for eight fluoroquinolones against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, methicillin-resistant Staphylococcus epidermidis, viridans streptococci, Enterobacter aerogenes, and Pseudomonas aeruginosa in rabbit or rat models. Enterococci were excluded because of poor bactericidal activity, A 24-hour area under the concentration curve (AUC)/minimal inhibitory concentration (MIC) ratio greater than or equal to 100, a peak level/MIC ratio > 8, and continuous levels above the time were associated with a significantly lower number of cfu per vegetation after 3-6 days of therapy, The 24-hour AUC/MIC exhibited the best linear correlation with cfu per vegetation after 3-6 days of therapy (r(2) = 45%). The pharmacodynamic parameters predictive of efficacy for fluoroquinolones in the treatment of experimental endocarditis are similar to those for other infectious models.
引用
收藏
页码:47 / 50
页数:4
相关论文
共 21 条
[1]   EFFICACY OF CIPROFLOXACIN IN EXPERIMENTAL AORTIC-VALVE ENDOCARDITIS CAUSED BY A MULTIPLY BETA-LACTAM-RESISTANT VARIANT OF PSEUDOMONAS-AERUGINOSA STABLY DEREPRESSED FOR BETA-LACTAMASE PRODUCTION [J].
BAYER, AS ;
LINDSAY, P ;
YIH, J ;
HIRANO, L ;
LEE, D ;
BLOMQUIST, IK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (04) :528-531
[2]   CIPROFLOXACIN IN EXPERIMENTAL AORTIC-VALVE ENDOCARDITIS DUE TO PSEUDOMONAS-AERUGINOSA [J].
BAYER, AS ;
BLOMQUIST, IK ;
KIM, KS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 17 (05) :641-649
[3]   ENOXACIN COMPARED WITH CEFOPERAZONE FOR THE TREATMENT OF EXPERIMENTAL ENTEROBACTER-AEROGENES ENDOCARDITIS [J].
BOSCIA, JA ;
KOBASA, WD ;
KAYE, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (05) :708-711
[4]   EFFICACY OF CIPROFLOXACIN FOR EXPERIMENTAL ENDOCARDITIS CAUSED BY METHICILLIN-SUSCEPTIBLE OR METHICILLIN-RESISTANT STRAINS OF STAPHYLOCOCCUS-AUREUS [J].
CARPENTER, TC ;
HACKBARTH, CJ ;
CHAMBERS, HF ;
SANDE, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (03) :382-384
[5]  
CRAIG W, 1995, EUR J CLIN MICROBIOL, V14, P4
[6]   EFFICACY OF TEMAFLOXACIN IN EXPERIMENTAL STREPTOCOCCUS-ADJACENS ENDOCARDITIS AND AUTORADIOGRAPHIC DIFFUSION PATTERN OF [C-14] TEMAFLOXACIN IN CARDIAC VEGETATIONS [J].
CREMIEUX, AC ;
SALEHMGHIR, A ;
VALLOIS, JM ;
MAZIERE, B ;
MUFFATJOLY, M ;
DEVINE, C ;
BOUVET, A ;
POCIDALO, JJ ;
CARBON, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (10) :2216-2221
[7]   PARENTERAL SPARFLOXACIN COMPARED WITH CEFTRIAXONE IN TREATMENT OF EXPERIMENTAL ENDOCARDITIS DUE TO PENICILLIN-SUSCEPTIBLE AND PENICILLIN-RESISTANT STREPTOCOCCI [J].
ENTENZA, JM ;
BLATTER, M ;
GLAUSER, MP ;
MOREILLON, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) :2683-2688
[8]   Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus [J].
Entenza, JM ;
Vouillamoz, J ;
Glauser, MP ;
Moreillon, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1662-1667
[9]   ENOXACIN COMPARED WITH VANCOMYCIN FOR THE TREATMENT OF EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
GILBERT, M ;
BOSCIA, JA ;
KOBASA, WD ;
KAYE, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (03) :461-463
[10]   ORAL TEMAFLOXACIN VERSUS VANCOMYCIN FOR THERAPY OF EXPERIMENTAL ENDOCARDITIS CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
HESSEN, MT ;
PITSAKIS, PG ;
KAYE, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1143-1145